CQ Pharmaceutical Holding Co Ltd

Discover how CQ Pharmaceutical Holding Co Ltd can capitalize on China’s booming medical‑commercial sector and supportive policies to boost logistics, inventory, and earnings.

CQ Pharmaceutical’s 10 % stock surge after signing a GLP‑1R licence with Pfizer signals a new revenue stream and a shift toward high‑margin obesity and type‑2 diabetes drugs.

CQ Pharmaceutical Holding Co Ltd’s mid-year financial results for 2025 show modest revenue growth and a significant increase in net profit, but a high price-to-earnings ratio raises concerns about overvaluation and potential future risks.